Inhibikase Therapeutics, Inc. Income Tax Expense
Inhibikase Therapeutics, Inc. (IKT) reported Income Tax Expense of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2026-06-30 was $0.00.
- Inhibikase Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2026-03-31 was $0.00.
- Inhibikase Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2025-12-31 was $0.00.
- Inhibikase Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2025-09-30 was $0.00.
- Inhibikase Therapeutics, Inc. income tax expense (benefit) for fiscal 2025 was $0.00.
- Inhibikase Therapeutics, Inc. income tax expense (benefit) for fiscal 2024 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |